Efficacy News and Research

RSS
Rexahn Pharmaceuticals submits Phase II protocol for study of Serdaxin in treatment of PD

Rexahn Pharmaceuticals submits Phase II protocol for study of Serdaxin in treatment of PD

Side effects may limit use of Prometheus's Lotronex for IBS

Side effects may limit use of Prometheus's Lotronex for IBS

Altheos to fund development of ATS907 Rho-kinase inhibitor with completed $20M Series A financing

Altheos to fund development of ATS907 Rho-kinase inhibitor with completed $20M Series A financing

Juventas Therapeutics commences enrollment in Phase I trial of JVS-100 for treatment of Class III heart failure

Juventas Therapeutics commences enrollment in Phase I trial of JVS-100 for treatment of Class III heart failure

Request for lift of full clinical hold on Proellex program

Request for lift of full clinical hold on Proellex program

Are Australians popping too many pills?

Are Australians popping too many pills?

New report assesses optimal future for REMS

New report assesses optimal future for REMS

Psychiatry expert on mission to test new theory of evidence-based flying

Psychiatry expert on mission to test new theory of evidence-based flying

Clinical utility and pharmacological action of MN-166 in treatment of MS

Clinical utility and pharmacological action of MN-166 in treatment of MS

Cancer research at Georgia Tech: Report

Cancer research at Georgia Tech: Report

Ultrasound and light for determining tumor's response to therapy in early stages

Ultrasound and light for determining tumor's response to therapy in early stages

Winner of 2010-2011 Luminex/ACMGF Award

Winner of 2010-2011 Luminex/ACMGF Award

Debate and skepticism over the healthcare reforms

Debate and skepticism over the healthcare reforms

Physicians increase prescription of new biologics

Physicians increase prescription of new biologics

UVA's DMT scanner helps detect breast cancer undetectable with mammography, MRI or needle biopsy

UVA's DMT scanner helps detect breast cancer undetectable with mammography, MRI or needle biopsy

UK NICE recommends Eli Lilly's ALIMTA as maintenance therapy for nonsquamous NSCLC

UK NICE recommends Eli Lilly's ALIMTA as maintenance therapy for nonsquamous NSCLC

Catalyst Pharmaceutical Partners reports net loss of $7.24M for fourth-quarter 2009

Catalyst Pharmaceutical Partners reports net loss of $7.24M for fourth-quarter 2009

Derma Sciences reports 69% increase in Advanced Wound Care sales for fourth-quarter 2009

Derma Sciences reports 69% increase in Advanced Wound Care sales for fourth-quarter 2009

Data of focusing on Rebif and Cladribine Tablets to be presented at AAN Annual Meeting

Data of focusing on Rebif and Cladribine Tablets to be presented at AAN Annual Meeting

Phase 1/2 human clinical trial of Symphogen's Sym004 initiated in the US

Phase 1/2 human clinical trial of Symphogen's Sym004 initiated in the US

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.